Literature DB >> 16339699

Does heterozygous beta-thalassemia confer a protection against coronary artery disease?

Stergios Tassiopoulos1, Spyros Deftereos, Kostas Konstantopoulos, Dimitris Farmakis, Maria Tsironi, Michalis Kyriakidis, Athanassios Aessopos.   

Abstract

Six hundred and thirty-eight patients who presented with clinical symptoms and/or electrocardiographic findings suggestive of stable angina pectoris were studied; they were also investigated by coronary arteriography. Hemoglobin electrophoresis was performed on all patients to detect the presence of the beta-thalassemia trait. Results were analyzed by logistic regression analysis to determine whether the latter confers any protective effect against advanced coronary artery disease (aCAD; defined as the presence of atheromas in coronary arteries, resulting in stenosis at least 70%). The role of the currently accepted risk factors (smoking, hypertension, hypercholesterolemia, and diabetes) in developing aCAD were reconfirmed, while at the same time it was found that beta-thalassemia heterozygosity is associated with a reduced risk against aCAD (odds ratio 0.39, 95% confidence interval 0.16-0.98). The lipoprotein and blood rheology profile of these individuals may be the underlying causes of this protective effect.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16339699     DOI: 10.1196/annals.1345.068

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  6 in total

1.  Impact of β-thalassemia trait carrier state on cardiovascular risk factors and metabolic profile in patients with newly diagnosed hypertension.

Authors:  A I Triantafyllou; G P Vyssoulis; E A Karpanou; P L Karkalousos; E A Triantafyllou; A Aessopos; D T Farmakis
Journal:  J Hum Hypertens       Date:  2013-10-24       Impact factor: 3.012

2.  Extracellular vesicles from thalassemia patients carry iron-containing ferritin and hemichrome that promote cardiac cell proliferation.

Authors:  Anyapat Atipimonpat; Panjaree Siwaponanan; Archrob Khuhapinant; Saovaros Svasti; Kasama Sukapirom; Ladawan Khowawisetsut; Kovit Pattanapanyasat
Journal:  Ann Hematol       Date:  2021-06-21       Impact factor: 3.673

3.  Pathophysiology and Clinical Manifestations of the β-Thalassemias.

Authors:  Arthur W Nienhuis; David G Nathan
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

Review 4.  Vascular complications after splenectomy for hematologic disorders.

Authors:  Shelley E Crary; George R Buchanan
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

Review 5.  Homing endonucleases: from basics to therapeutic applications.

Authors:  Maria J Marcaida; Inés G Muñoz; Francisco J Blanco; Jesús Prieto; Guillermo Montoya
Journal:  Cell Mol Life Sci       Date:  2010-03       Impact factor: 9.261

6.  Coronary atherosclerosis burden is not advanced in patients with β-thalassemia despite premature extracardiac atherosclerosis: a coronary artery calcium score and carotid intima-media thickness study.

Authors:  George Hahalis; Evangelia Zacharioglou; Ioanna Xanthopoulou; Ioanna Koniari; Chistina Kalogeropoulou; Irene Tsota; Aspasia Rigopoulou; Athanasios Diamantopoulos; Vasilios Gkizas; Periklis Davlouros; Karolina Akinosoglou; Marianna Leopoulou; Charalampos Gogos; Dimitrios Alexopoulos
Journal:  J Geriatr Cardiol       Date:  2016-02       Impact factor: 3.327

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.